



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

1.3 Product Information

1.3.1 Summary of Product Characteristics (SmPC)

1. Name of the medicinal product:

Generic Name/INN Name: Amoxicillin and Clavulanate Potassium Tablets USP 625 mg

Trade Name: CHEMOCLAV 625

Strength:

Each film coated tablet contains:

Amoxicillin Trihydrate BP

Equivalent to Amoxicillin.....500 mg

Potassium Clavulanate BP

(As Potassium Clavulanate Diluted BP)

Equivalent to Clavulanic Acid.....125 mg

Excipients..... q.s.

Colour: Titanium Dioxide

**MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT****2. Qualitative and Quantitative composition:**

| Sr. No. | Ingredients | Spec. | Label Claim (mg) | % O.A | Std. Qty./Tablet(mg) | % w/w | Function |
|--|--|----------|------------------|-------|----------------------|---------|------------------|
| Dry Mixing | | | | | | | |
| 1. | Amoxicillin trihydrate BP eq. to Amoxicillin* | BP | 500.00 | 0.0% | 500.00 | 43.70 | Active |
| 2 | Clavulanate Potassium with Avicel 1:1 Ratio (MCC)* | BP | 125.00 | 5.0% | 125.00 | 10.92 | Active |
| 4. | Microcrystalline Cellulose (112)** | BP | -- | 0.0% | 433.750 | 37.91 | Diluent |
| 5. | Sodium Starch Glycolate | BP | -- | 0.0% | 20.000 | 1.74 | Disintegrant |
| 6. | Colloidal Silicon Dioxide | BP | -- | 0.0% | 5.000 | 0.43 | Glidant |
| Lubrication | | | | | | | |
| 7. | Magnesium Stearate | BP | -- | 0.0% | 10.000 | 0.87 | Lubricant |
| Total weight of uncoated tablet | | | | | 1100.00 | -- | -- |
| Coating | | | | | | | |
| 8. | Isopropyl Alcohol*** | BP | -- | 0.0% | 396.00 | -- | Solvent |
| 9. | Dichloromethane*** | BP | -- | 0.0% | 594.00 | -- | Solvent |
| 10. | Col. Opadry White | In-House | -- | 0.0% | 44.00 | 3.84 | Coating Material |
| Total weight of coated tablet | | | | | 1144.00 | 100.00% | |

* The quantity of the Amoxicillin Trihydrate & Clavulanate Potassium has to be calculated as per the Assay & Water content.

** Quantity of Microcrystalline Cellulose will vary as per the quantity of the APIs.

*** Used in coating suspension preparation and it is evaporated on drying.



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

3. Pharmaceutical form:

Dosage Form:

Solid Oral Dosage form (Tablet)

Visual & Physical characteristics of the product:

A white colored, oval shape, biconvex, film coated tablets, having breakline on one side of the tablets.

4. Clinical particulars:

4.1 Therapeutic indications:

Amoxicillin and Clavulanate Potassium Tablets USP 625 mg is indicated for the treatment of the following infections in adults & children.

- Acute bacterial sinusitis (adequately diagnosed)
- Acute otitis media
- Acute exacerbations of chronic bronchitis (adequately diagnosed)
- Community acquired pneumonia
- Cystitis
- Pyelonephritis
- Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.
- Bone and joint infections, in particular osteomyelitis.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration:

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Adults and children weighing 40 kg and over

- Usual dose – 1 tablet two times a day
- Higher dose – 1 tablet three times a day

Children weighing less than 40 kg



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

Ask your doctor or pharmacist for advice when giving Amoxicillin and clavulanate potassium tablets USP 625 mg tablets to children weighing less than 40 kg. The tablets are not suitable for children weighing less than 25 kg.

Patients with kidney and liver problems

- If you have kidney problems the dose might be changed. A different strength or a different medicine may be chosen by your doctor.
- If you have liver problems you may have more frequent blood tests to see how your liver is working.

Method of administration:

- Swallow the tablets whole with a glass of water with a meal. Tablets can be broken along the score line to make them easier to swallow. You must take both pieces of the tablet at the same time.
- Space the doses evenly during the day, at least 4 hours apart. Do not take 2 doses in 1 hour.
- Do not take Amoxicillin and Clavulanate potassium tablets USP 625 mg for more than 2 weeks.

4.3 Contraindications:

Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients listed in section 1.3.6.1.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid.

4.4 Special warnings and precautions for use:

Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents.

Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.

This presentation of amoxicillin and clavulanate potassium USP 625 mg is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid. This presentation should not be used to treat penicillin-resistant *S. pneumoniae*. Convulsions may occur in patients with impaired renal function or in those receiving high doses.

Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin. Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. Prolonged use may occasionally result in overgrowth of non-susceptible organisms. The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP). This reaction requires amoxicillin and clavulanate potassium discontinuation and contraindicates any subsequent administration of amoxicillin. Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment.

Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and, in extremely rare circumstances deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects.

Antibiotic-associated colitis has been reported with nearly all antibacterial agents including amoxicillin and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contraindicated in this situation.

Periodic assessment of organ system functions; including renal, hepatic and haematopoietic function is advisable during prolonged therapy.

Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

In patients with renal impairment, the dose should be adjusted according to the degree of impairment. patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained.

During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non-enzymatic methods.

The presence of clavulanic acid in amoxicillin and clavulanate potassium may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.

There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

4.5 Interaction with other medicinal products and other forms of interaction

Oral anticoagulants

Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary.

Methotrexate

Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.

Probenecid

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.

Mycophenolate mofetil

In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.

4.6 Fertility, Pregnancy and lactation:

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Limited data on the use of amoxicillin/clavulanic acid during pregnancy in humans do not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane it was reported that prophylactic treatment with amoxicillin/clavulanic acid may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.

**MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT**Breastfeeding

Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. The possibility of sensitisation should be taken into account. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.

4.7 Effects on ability to drive and use machines:

No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines.

4.8 Undesirable effects:

| | |
|--|-----------|
| Infections and infestations | |
| Mucocutaneous candidosis | Common |
| Overgrowth of non-susceptible organisms | Not known |
| Blood and lymphatic system disorders | |
| Reversible leucopenia (including neutropenia) | Rare |
| Thrombocytopenia | Rare |
| Reversible agranulocytosis | Not known |
| Haemolytic anaemia | Not known |
| Prolongation of bleeding time and prothrombin time | Not known |
| Immune system disorders | |
| Angioneurotic oedema | Not known |
| Anaphylaxis | Not known |
| Serum sickness-like syndrome | Not known |
| Hypersensitivity vasculitis | Not known |
| Nervous system disorders | |
| Dizziness | Uncommon |
| Headache | Uncommon |
| Reversible hyperactivity | Not known |
| Convulsions | Not known |
| Aseptic meningitis | Not known |
| Gastrointestinal disorders | |

**MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT**

| | |
|---|-------------|
| Diarrhoea | Very common |
| Nausea | Common |
| Vomiting | Common |
| Indigestion | Uncommon |
| Antibiotic-associated colitis | Not known |
| Black hairy tongue | Not known |
| Hepatobiliary disorders | |
| Rises in AST and/or ALT ⁵ | Uncommon |
| Hepatitis ⁶ | Not known |
| Cholestatic jaundice | Not known |
| Skin and subcutaneous tissue disorders ⁷ | |
| Skin rash | Uncommon |
| Pruritus | Uncommon |
| Urticaria | Uncommon |
| Erythema multiforme | Rare |
| Stevens-Johnson syndrome | Not known |
| Toxic epidermal necrolysis | Not known |
| Bullous exfoliative-dermatitis | Not known |
| Acute generalised exanthemous pustulosis (AGEP) | Not known |
| Drug reaction with eosinophilia and systemic symptoms (DRESS) | Not known |
| Renal and urinary disorders | |
| Interstitial nephritis | Not known |
| Crystalluria | Not known |

4.9 Overdose:Symptoms and signs of overdose

Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed. Convulsions may occur in patients with impaired renal function or in those receiving high doses. Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses. A regular check of patency should be maintained.

Treatment of intoxication



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.

Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.

5. Pharmacological properties:

5.1 Pharmacodynamic properties:

Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors;

ATC code: J01CR02.

Mechanism of action

Amoxicillin is semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.

Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.

Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.

Pharmacokinetic/pharmacodynamic relationship

The time above the minimum inhibitory concentration ($T > MIC$) is considered to be the major determinant of efficacy for amoxicillin.

Mechanisms of resistance

The two main mechanisms of resistance to amoxicillin/clavulanic acid are:

- Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.
- Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.

Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.

Breakpoints



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

MIC breakpoints for amoxicillin/clavulanic acid are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

| Organism | Susceptibility Breakpoints (µg/ml) | | |
|---|------------------------------------|--------------|-----------|
| | Susceptible | Intermediate | Resistant |
| <i>Haemophilus influenzae</i> ¹ | ≤ 1 | - | > 1 |
| <i>Moraxella catarrhalis</i> ¹ | ≤ 1 | - | > 1 |
| <i>Staphylococcus aureus</i> ² | ≤ 2 | - | > 2 |
| Coagulase-negative staphylococci ² | ≤ 0.25 | | > 0.25 |
| <i>Enterococcus</i> ¹ | ≤ 4 | 8 | > 8 |
| <i>Streptococcus A, B, C, G</i> ⁵ | ≤ 0.25 | - | > 0.25 |
| <i>Streptococcus pneumoniae</i> ³ | ≤ 0.5 | 1-2 | > 2 |
| Enterobacteriaceae ^{1,4} | - | - | > 8 |
| Gram-negative Anaerobes ¹ | ≤ 4 | 8 | > 8 |
| Gram-positive Anaerobes ¹ | ≤ 4 | 8 | > 8 |
| Non-species related breakpoints ¹ | ≤ 2 | 4-8 | > 8 |

¹ The reported values are for amoxicillin concentrations. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/l.

² The reported values are oxacillin concentrations.

³ Breakpoint values in the table are based on ampicillin breakpoints.

⁴ The resistant breakpoint of R>8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.

⁵ Breakpoint values in the table are based on benzylpenicillin breakpoints.

The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

| <u>Commonly susceptible species</u> |
|--|
| <u>Aerobic Gram-positive micro-organisms</u> |
| <i>Enterococcus faecalis</i> |
| <i>Gardnerella vaginalis</i> |
| <i>Staphylococcus aureus</i> (methicillin-susceptible)‡ |
| Coagulase-negative staphylococci (methicillin-susceptible) |
| <i>Streptococcus agalactiae</i> |
| <i>Streptococcus pneumoniae</i> ¹ |
| <i>Streptococcus pyogenes</i> and other beta-haemolytic streptococci |



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

Streptococcus viridans group
Aerobic Gram-negative micro-organisms

Capnocytophaga spp.

Eikenella corrodens

Haemophilus influenzae²

Moraxella catarrhalis

Pasteurella multocida

Anaerobic micro-organisms

Bacteroides fragilis

Fusobacterium nucleatum

Prevotella spp.

Species for which acquired resistance may be a problem

Aerobic Gram-positive micro-organisms

Enterococcus faecium \$

Aerobic Gram-negative micro-organisms

Escherichia coli

Klebsiella oxytoca

Klebsiella pneumoniae

Proteus mirabilis

Proteus vulgaris

Inherently resistant organisms

Aerobic Gram-negative micro-organisms

Acinetobacter sp.

Citrobacter freundii

Enterobacter sp.

Legionella pneumophila

Morganella morganii

Providencia spp.

Pseudomonas sp.

Serratia sp.

Stenotrophomonas maltophilia

Other micro-organisms

Chlamydomonas pneumoniae

Chlamydomonas psittaci

Coxiella burnetii

Mycoplasma pneumoniae

\$ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.

£ All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid

¹ *Streptococcus pneumoniae* that are resistant to penicillin should not be treated with this presentation of amoxicillin/clavulanic acid .

² Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

5.2 Pharmacokinetic properties:

Absorption

Amoxicillin and clavulanic acid, are fully dissociated in aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral route of administration. Following oral administration, amoxicillin and clavulanic acid are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (T_{max}) in each case is approximately one hour. The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (500 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers, are presented below.

| Mean (\pm SD) pharmacokinetic parameters | | | | | |
|---|-----------|-------------------------|------------------|-----------------------------|--------------------|
| Active substance(s) administered | Dose (mg) | C_{max} (μ g/ml) | T_{max} * (h) | AUC (0-24h) (μ g.h/ml) | T 1/2 (h) |
| Amoxicillin | | | | | |
| AMX/CA 500/125 mg | 500 | 7.19 \pm 2.26 | 1.5 (1.0-2.5) | 53.5 \pm 8.87 | 1.15 \pm 0.20 |
| Clavulanic acid | | | | | |
| AMX/CA 500 mg/125 mg | 125 | 2.40 \pm 0.83 | 1.5 (1.0-2.0) | 15.72 \pm 3.86 | 0.98 \pm 0.12 |
| AMX – amoxicillin, CA – clavulanic acid * Median (range) | | | | | |

Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.

Distribution

About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid. Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid. From animal studies there is no evidence for



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk. Both amoxicillin and clavulanic acid have been shown to cross the placental barrier.

Biotransformation: Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces, and as carbon dioxide in expired air.

Elimination

The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.

Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of single amoxicillin and clavulanate potassium BP 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration. Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid.

Age

The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.

Renal impairment



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted *via* the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid.

Hepatic impairment

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

5.3 Preclinical safety data

Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.

Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.

Carcinogenicity studies have not been conducted with amoxicillin/clavulanic acid or its components.

6. Pharmaceutical particulars:

6.1 List of Excipients:

Microcrystalline Cellulose (112) BP

Sodium Starch Glycolate BP

Colloidal Silicon Dioxide BP

Magnesium Stearate BP

Col. Opadry White (In-House)

6.2 Incompatibilities:

Not applicable

6.3 Shelf life:

24 months

6.4 Special precautions for storage:

Store below 30°C in a dry place. Protect from light.



MODULE 1- ADMINISTRATIVE PARTICULARS OF THE PRODUCT

6.5 Nature and contents of container:

7 tablets in one ALU-ALU blister. Such 2 blister packed in one monocarton along with pack insert.

6.6 Special precautions for disposal:

No special requirements.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Applicant:

Chez Resources Pharmaceutical Limited

No. 7, Calabar Street, Fegge, Onitsha, Anambra State, NIGERIA

Manufacturer:

Bharat Parenterals Limited,
Survey No. 144-A, Jarod Samlaya Road,
Village: Haripura, Tal.- Savli,
Dist.Vadodara-391520,
Gujarat, India